3,004 results on '"Kesselheim, Aaron S."'
Search Results
202. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
203. Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms.
204. Propofol as a transformative drug in anesthesia: insights from key early investigators
205. Alternatives to the quality‐adjusted life year: How well do they address common criticisms?
206. Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
207. Reforming the World Health Organization’s Essential Medicines List
208. Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
209. Patient Out‐of‐Pocket Costs Following the Availability of Biosimilar Versions of Infliximab
210. Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016
211. Holding Pharmaceutical and Medical Device Executives Accountable as Responsible Corporate Officers
212. Medicaid Spending on Antiretrovirals From 2007 Through 2019
213. Recent Trends in Prescription Drug Launch Prices—Reply
214. Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D
215. Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study
216. Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence
217. Active Surveillance of Follow-on Biologics: A Prescription for Uptake
218. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014 : cohort study
219. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14 : systematic review
220. A New Wave of Vaccines for Non-Communicable Diseases : What Are the Regulatory Challenges?
221. Expansion of the Priority Review Voucher Program Under the 21st Century Cures Act: Implications for Innovation and Public Health
222. Innovative research methods for studying treatments for rare diseases : methodological review
223. Blueprint for Transparency at the U.S. Food and Drug Administration: Recommendations to Advance the Development of Safe and Effective Medical Products
224. Desmopressin and the risk of hyponatremia: A population-based cohort study
225. Extent of Drug Patents With Terminal Disclaimers and Obviousness-Type Double Patenting Rejections.
226. Drug Repurposing Via the Best Pharmaceuticals for Children Act.
227. The Origins of "Confidential Commercial Information" at the FDA.
228. Correction to: FDA and EMA Biosimilar Approvals
229. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US an Europe From 2007 to 2021
230. Limitations on the Capability of the FDA to Advise
231. New Reforms to Prescription Drug Pricing in the US
232. Antibody Patent Evolution
233. Drug Repurposing: Legal and Regulatory Issues in the US
234. Improving the Use of FDA Advisory Committees
235. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
236. Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments
237. Characteristics Of Key Patents Covering Recent FDA-Approved Drugs
238. The Vexing Voyage of Vasopressin
239. What to Know About the Alzheimer Drug Aducanumab (Aduhelm)
240. The History of Health Law in the United States
241. Fundamentals of Health Law — A New Perspective Series
242. The Bayh-Dole Act at 40: Accomplishments, Challenges, and Possible Reforms
243. Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review
244. Over-the-Counter Availability of Rescue Inhalers for Asthma—Reply
245. Institutionalizing Misinformation — The Dietary Supplement Listing Act of 2022
246. Payments for research participation: Don’t tax the Guinea pig
247. Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company
248. Legal Challenges to State Drug Pricing Laws
249. Studying new antibiotics for multidrug resistant infections: are todayʼs patients paying for unproved future benefits?
250. Regulating incremental innovation in medical devices
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.